Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women.
Serum IGF-I level was negatively correlated with OPG and OPG/RANKL ratio, but positively correlated with RANKL. Serum OPG level in the highest quintile of IGF-I was significantly lower than that in the lowest. We conclude that the effect of IGF-I on bone remodeling may be mediated by the OPG/RANKL system.


BACKGROUND
Insulin-like growth factor I (IGF-I) is an important factor in coupling bone remodeling, activating both formation and resorption. Compared with the many studies on the role of IGF-I in bone formation, the information regarding its effects on bone resorption is limited and conflicting. The balance of the two peptides produced by osteoblasts, osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand (RANKL), is critical for the bone resorption process. Our study was designed to analyze the relationships of serum concentrations of IGF-I with OPG, RANKL, OPG/RANKL ratio as well as BMDs in healthy Chinese women.


METHODS
BMDs at lumbar spine and proximal femur in 504 pre- and postmenopausal women were measured by DXA. Serum levels of IGF-I, OPG and RANKL were also measured. Pearson's correlation and partial correlation analysis, ANOVA, covariance analysis and stepwise multiple regression analysis were used as appropriate.


RESULTS
Age was negatively correlated with serum levels of IGF-I (r = -0.702, p < 0.001). IGF-I was negatively correlated with OPG and OPG/RANKL ratio, but positively correlated with RANKL. The relationship between IGF-I and BMDs disappeared after adjustment for age. In postmenopausal women, IGF-I was lower in women with osteoporosis than in those with normal BMD (p = 0.056), but no differences were found among OPG, RANKL and OPG/RANKL ratio. Serum levels of OPG in the highest quintile of IGF-I were significantly lower than those in the lowest quintile of IGF-I, while no difference was found in RANKL. In the multiple regression analysis model, serum levels of IGF-I were the main determinants of the bone mass in Chinese women.


CONCLUSIONS
In conclusion, the relationship between decreasing IGF-I and BMDs in healthy Chinese women influenced by age, whereas the effect of IGF-I on bone remodeling (bone resorption) may be mediated by the OPG/RANKL system.
Zhao
H-Y
HY
Shanghai Clinical Center for Endocrine and Metabolic Diseases, Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 197 Ruijin Er Road, 200025 Shanghai, China.
Liu
J-M
JM
Ning
G
G
Zhao
Y-J
YJ
Chen
Y
Y
Sun
L-H
LH
Zhang
L-Z
LZ
Xu
M-Y
MY
Chen
J-L
JL
D000328:Adult; D000375:Aging / Q000097:blood / Q000502:physiology; D015519:Bone Density / Q000502:physiology*; D001851:Bone Diseases, Metabolic / Q000097:blood / Q000503:physiopathology; D005260:Female; D005269:Femur / Q000502:physiology; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism* / Q000502:physiology; D008159:Lumbar Vertebrae / Q000502:physiology; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000097:blood / Q000503:physiopathology; D053244:Osteoprotegerin / Q000097:blood* / Q000502:physiology; D017698:Postmenopause / Q000097:blood / Q000502:physiology; D053245:RANK Ligand / Q000097:blood* / Q000502:physiology
D053244:Osteoprotegerin; D053245:RANK Ligand; C506030:TNFRSF11B protein, human; C505688:TNFSF11 protein, human; D007334:Insulin-Like Growth Factor I
Endocrinology. 2001 Oct;142(10):4349-56
11564695
Endocrinology. 1999 Aug;140(8):3552-61
10433211
J Bone Miner Res. 1997 Aug;12 (8):1272-9
9258758
Eur J Endocrinol. 1995 Mar;132(3):313-9
7889180
Exp Biol Med (Maywood). 2003 Mar;228(3):245-52
12626768
Bone. 1999 Apr;24(4):387-93
10221551
Endocrinology. 2001 Aug;142(8):3546-53
11459801
Endocrinology. 1995 Jan;136(1):124-31
7828521
Biochem Biophys Res Commun. 2006 Aug 25;347(2):460-7
16828054
Cell. 1997 Apr 18;89(2):309-19
9108485
Endocrinology. 2000 Jul;141(7):2674-82
10875273
Endocrinology. 2001 Dec;142(12):5050-5
11713196
Exp Cell Res. 2004 Mar 10;294(1):149-58
14980510
Cell. 1998 Apr 17;93(2):165-76
9568710
Eur J Endocrinol. 2005 Mar;152(3):327-32
15757846
World Health Organ Tech Rep Ser. 1994;843:1-129
7941614
Bone. 1996 Mar;18(3):269-76
8703583
J Biol Chem. 1999 May 7;274(19):13613-8
10224132
J Clin Endocrinol Metab. 2001 Jul;86(7):3162-5
11443182
Eur J Clin Invest. 1997 Apr;27(4):322-6
9134381
Curr Pharm Des. 2001 May;7(8):613-35
11375772
Endocrinology. 1999 Oct;140(10):4382-9
10499489
Calcif Tissue Int. 1993 Jul;53(1):1-6
8348380
J Clin Endocrinol Metab. 2001 Apr;86(4):1496-503
11297574
Endocrinology. 2001 Sep;142(9):4047-54
11517184
J Clin Endocrinol Metab. 2002 Sep;87(9):4273-9
12213884
J Bone Miner Res. 2001 Dec;16(12):2320-9
11760848
Bone. 2001 Jan;28(1):113-7
11165951
Calcif Tissue Int. 2005 Jan;76(1):1-6
15455183
J Clin Endocrinol Metab. 1998 Jul;83(7):2331-7
9661604
J Clin Endocrinol Metab. 1998 Dec;83(12):4257-62
9851760
J Bone Miner Res. 2006 Sep;21(9):1350-8
16939393
Bone. 1997 Sep;21(3):215-6
9276085